CAR-T Cell Therapy for Solid Tumors: 2026 Clinical Trial Breakthroughs
By Dr. Sarah Mitchell, Respiratory Equipment Specialist · Published 2026-05-15 · 11 min read
Once limited to blood cancers, engineered T-cells are now showing dramatic responses in lung, pancreatic, and brain tumors. See the latest trial results.
Beyond Blood Cancers
Chimeric antigen receptor T-cell (CAR-T) therapy transformed leukemia and lymphoma care. In 2026, four new CAR-T constructs are showing meaningful efficacy against solid tumors for the first time.
Top 2026 Solid-Tumor CAR-T Programs
- CLDN18.2 CAR-T (gastric, pancreatic): 57% response rate
- MUC16 CAR-T (ovarian): 41% response rate
- B7-H3 CAR-T (glioblastoma): unprecedented complete responses
- EGFR CAR-T (NSCLC): 33% response, improved overall survival
Respiratory Cancer Implications
For non-small cell lung cancer (NSCLC) patients who progressed on immunotherapy, EGFR-targeted CAR-T is offering a new option. Many trial patients continue portable oxygen therapy during treatment — battery-efficient units like those listed at portable oxygen support active treatment schedules.